F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comAnthem BioSciences Ltd is a fast-growing player in the Indian biotechnology and pharmaceutical services industry. Known for its innovation-led research and manufacturing capabilities, Anthem Bio has attracted investor attention since its market debut. With strong promoter holding, strategic business focus, and rising market valuation, this article explores Anthem BioSciences’ share price targets from 2025 to 2030 and offers investment insights.
Let’s analyze the company’s current performance, key metrics, and its long-term price target outlook.
| Detail | Value |
|---|---|
| Current Price | ₹731.15 |
| Previous Close | ₹730.35 |
| Day's High | ₹752.70 |
| Day's Low | ₹701.90 |
| 52-Week High | ₹752.70 |
| 52-Week Low | ₹701.90 |
| All-Time High | ₹752.70 |
| All-Time Low | ₹701.90 |
| Market Capitalization | ₹40,983 Cr |
| Volume (Shares) | 1.21 Crore |
| Value (Lacs) | ₹88,306.17 |
| VWAP | ₹734.03 |
| Face Value | ₹2 |
| Beta (Volatility) | 0.00 (New Listing) |
Anthem BioSciences is a contract research and manufacturing organization (CRAMO) engaged in the development and production of pharmaceutical intermediates, APIs, and biotechnology-based products. The company focuses on innovation, R&D, and scalable manufacturing that supports global pharma companies.
Strong R&D capability with state-of-the-art labs
Strategic partnerships with global pharma and biotech firms
Robust order book from CDMO (Contract Development and Manufacturing Organization) services
Recent market listing with strong debut
Promoter holding of 74.69% indicates high confidence
| Investor Type | Holding (%) |
|---|---|
| Promoters | 74.69% |
| Retail & Others | 20.46% |
| Mutual Funds | 2.21% |
| Foreign Institutions | 1.50% |
| Other Domestic Institutions | 1.14% |
This shareholding structure shows that Anthem BioSciences is largely promoter-driven with increasing interest from mutual funds and retail investors.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 720 | 770 |
| 2026 | 780 | 860 |
| 2027 | 870 | 980 |
| 2028 | 990 | 1,100 |
| 2029 | 1,120 | 1,280 |
| 2030 | 1,300 | 1,500 |
These projections are based on Anthem Bio’s R&D pipeline, increasing CDMO contracts, global expansion plans, and steady operational growth.
Why?
Stable listing performance
Growing demand for CDMO and biotech solutions
Positive sentiment among retail investors
Investment Advice:
Ideal for early entry. Accumulate on dips for long-term gains as the company stabilizes post-listing.
Why?
Anticipated margin expansion through efficient operations
First full-year post-IPO financials expected to be strong
Growing institutional interest
Investment Advice:
Hold existing positions. Add during market corrections. Monitor quarterly performance closely.
Why?
International business scale-up
Expansion of R&D and new product launches
Rise in revenue visibility from long-term contracts
Investment Advice:
Retain shares for medium-term wealth creation. Suitable for investors seeking biotech sector exposure.
Why?
Strong balance sheet and potential for dividend initiation
Introduction of new therapeutic segments
Likely entry into Nifty Smallcap or Midcap indices
Investment Advice:
Reinvest profits. Maintain allocation within portfolio for defensive sector exposure.
Why?
Consistent YoY profit growth
Cost optimization and global client expansion
Increased R&D investment payoff
Investment Advice:
Ideal to continue holding or increase exposure gradually. Growth story still intact.
Why?
Potential leadership in CRAMO space in India
Global FDA approvals for manufacturing facilities
Diversification into biosimilars or oncology-based products
Investment Advice:
Strong long-term investment potential. Can be a multibagger for patient investors.
Yes, if you're looking for high-potential growth in the pharmaceutical and biotechnology sector. The company’s operational focus, promoter confidence, and strategic business model make it suitable for long-term portfolios.
High promoter holding ensures aligned interests
Strong market demand for outsourced pharmaceutical research and manufacturing
Competitive edge in R&D and manufacturing scale
Early stage of listing — scope for future re-rating
Market volatility due to lack of historical performance
Dependency on global regulatory approvals
High competition from other CDMOs and API firms
Earnings visibility still evolving post-IPO
Always seek financial advice before making significant investment decisions.
Anthem BioSciences Ltd has entered the Indian stock market with strong fundamentals and significant future potential. Currently trading around ₹731, the company could see a target price of ₹1,500 by 2030, making it a promising investment in the healthcare and biotech space.
With a high promoter stake, a robust order book, and growing investor interest, Anthem BioSciences could become a market leader in contract manufacturing and R&D services.
Stay updated with earnings reports and announcements, and consider phased investments for long-term wealth generation.
1. What is the current share price of Anthem BioSciences Ltd?
As of July 22, 2025, it is ₹731.15.
2. Is Anthem BioSciences a good stock to buy?
Yes, for long-term investors interested in the biotechnology and healthcare manufacturing sector.
3. What is the share price target of Anthem BioSciences in 2025?
Between ₹720 and ₹770 based on market trends and business performance.
4. What is the market cap of Anthem BioSciences?
₹40,983 Crore as of July 2025.
5. Who are the major shareholders in Anthem BioSciences?
Promoters hold 74.69%, with retail investors holding 20.46%.
6. What is Anthem Bio’s business model?
It provides CDMO, pharmaceutical R&D, and biotech manufacturing services to global clients.
Disclaimer: This article is for informational purposes only. Please consult a certified financial advisor before making any investment decisions.
Register & Login